While monotherapy with either IDO (epacadostat) or COX2 inhibitor (celecoxib) had no significant effect on tumor growth and malignant ascites, concurrent blockade of COX2 and/or PD-1 further strengthened the antitumor and anti-ascitic effects of STING agonist. Here, STING1 is linked to neoplasm.